Comando para Ignorar Faixa de Opções
Ir para o conteúdo principal

 Cap. 3 - Obesidade: Tratamento

1. Jeffreys M, McCarron P, Gunnell D, McEwen J, Smith GD. Body mass index in early and mid-adulthood, and subsequent mortality: a historical cohort study. Int J Obes Relat Metab Disord 2003;27:1391-7.

2. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097-105.

3. McGuire MT, Wing RR, Klem ML, Hill JO. Behavioral strategies of individuals who have maintained long-term weight losses. Obes Res 1999;7:334-41.

4. Silverstone JT, Turner P, Humpherson PL. Direct measurement of the anorectic activity of diethylpropion (Tenuate Dospan). J Clin Pharmacol J New Drugs 1968;8:172-9.

5. Bolding OT. A double-blind evaluation of tenuate dospan in overweight patients from a private gynecologic practice. J Med Assoc State of Alabama 1968;38:209-12.

6. McQuarrie HG. Clinical assessment of the use of an anorectic drug in a total weight reduction program. Curr Ther Res Clin Exp 1975;17:437-43.

7. McKay RH. Long-term use of diethylpropion in obesity. Curr Med Res Opin 1973;1:489-93.

8. Heber KR. Double-blind trial of mazindol in overweight patients. Med J Aust 1975;2:566-7.

9. Maclay WP, Wallace MG. A multi-centre general practice trial of mazindol in the treatment of obesity. Practioner 1977;218:431-4.

10. Slama G, Selmi A, Hautecouverture M, Tchobroutsky G. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients. Diabete Metab 1978;4:193-9.

11. Yoshida T, Sakane N, Umekawa T, Yoshioka K, Kondo M, Wakabayashi Y. Usefulness of mazindol in combined diet therapy consisting of a low-calorie diet and Optifast in severely obese women. Int J Clin Pharmacol Res 1994;14:125-32.

12. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000;117:870-4.

13. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003.

14. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000;94:152-8.

15. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002;144:508-15.

16. McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26:125-31.

17. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000;2:175-87.

18. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25.

19. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996;156:661-6.

20. McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26:125-31.

21. Yee EBJ, Phillips CL, Banerjee D, Caterson I, Hedner JA, Grunstein RR. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. International Journal of Obesity 2007;31:161-8.

22. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235-42.

23. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21:1288-94.

24. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61.

25. Muls E, Kolanowski J, Scheen A, van gaal l; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001;25(11):1713-21.

26. Nelson H, Robert M, Miles J. Use of orlistat in obese, dyslipidemic patients. Future Lipidology 2006;1(3):267-73.

27. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12(3):189-92.

28. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991;54:321-5.

Para mais informações ligue para tel (11) 3155-0854